EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.4.1.41 | Adenocarcinoma |
9354435 |
Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines. |
causal interaction
diagnostic usage
ongoing research
unassigned |
3
1
3
0 |
| 2.4.1.41 | Adenocarcinoma |
10626815 |
Structural basis for the regulation of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. |
ongoing research
unassigned |
2
0 |
| 2.4.1.41 | Adenocarcinoma |
11932895 |
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
4
4
1 |
| 2.4.1.41 | Adenocarcinoma |
14555840 |
Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
4
4
1 |
| 2.4.1.41 | Adenocarcinoma |
23659732 |
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
4
4
4 |
| 2.4.1.41 | Adenocarcinoma |
24619076 |
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. |
diagnostic usage
ongoing research
unassigned |
4
4
0 |
| 2.4.1.41 | Adenocarcinoma |
26604783 |
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification. |
causal interaction
diagnostic usage
ongoing research
unassigned |
3
4
4
0 |
| 2.4.1.41 | Adenocarcinoma |
26848976 |
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
3
1
0 |
| 2.4.1.41 | Adenocarcinoma |
30323967 |
The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
3
2
1 |
| 2.4.1.41 | Adenocarcinoma |
31888240 |
The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
2
3
1
0 |
